Stock 4552 JCR PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases JCR Pharmaceuticals Co., Ltd.

Equities

4552

JP3701000006

Delayed Japan Exchange
Other stock markets
 03:30:00 09/05/2024 BST 		5-day change 1st Jan Change
801 JPY +0.12% Intraday chart for JCR Pharmaceuticals Co., Ltd. -0.62% -31.66%
04-25 JCR Pharmaceuticals Co., Ltd. Announces Management Changes, Effective as of June 26, 2024 CI
03-21 US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion
AQ
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with Alexion
BU
JCR Pharmaceuticals Celebrates Rare Disease Day 2024 and Highlights Its Commitment to the Rare Disease Community
BU
JCR Pharmaceuticals Research Presentations at WORLDSymposium 2024 Showcase JR-141 and Other Investigational Treatments for Lysosomal Storage Disorders
AQ
JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders
BU
JCR Pharmaceuticals to Present at the 20th Annual WORLDSymposium™ 2024
BU
JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration
BU
JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® Technology
BU
U.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)
BU
Mucopolysaccharidosis Type I Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA
BU
JCR Pharmaceuticals : FY2023 First-Half Results Briefing Session -Material-（2,157KB）
PU
PHC IVD and JCR Announce Upgrade of Melon Nikki, Medication Management App for Pediatric Patients Undergoing Growth Hormone Therapy
AQ
JCR Pharmaceuticals Announces 52-week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I
AQ
JCR Pharmaceuticals Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)
BU
PHC and JCR Pharmaceuticals Jointly Develop and Launch Sales of Electric Injector 'Growject Duo' Exclusively for Human Growth Hormone Preparation 'Growject'
AQ
JCR Pharmaceuticals : FY2023-Q1 Financial Report (Apr. 1-Jun. 30, 2023)（413KB）
PU
JCR Pharmaceuticals : FY2022 Second-Half Results Briefing Session -Financial Results -（962KB）
PU
JCR Pharmaceuticals : FY2022 Full Year Financial Report（475KB）
PU
JCR Pharmaceuticals : FY2022 Second-Half Results Briefing Session -Script-（6,169KB）
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4552 Stock
  4. News JCR Pharmaceuticals Co., Ltd.
  5. Press Releases